Welcome to our dedicated page for Adc Therapeutics Sa news (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on Adc Therapeutics Sa stock.
ADC Therapeutics SA (NYSE: ADCT) is a commercial-stage oncology company focused on antibody drug conjugates, and its news flow centers on clinical progress, regulatory developments, and corporate updates. The company’s primary product, ZYNLONTA (loncastuximab tesirine-lpyl), is a CD19-directed ADC approved under accelerated and conditional pathways for certain adults with relapsed or refractory diffuse large B-cell lymphoma after at least two prior systemic therapies.
News about ADCT commonly includes updates from its LOTIS clinical program, such as the Phase 3 LOTIS-5 trial of ZYNLONTA plus rituximab in second-line or later DLBCL and the Phase 1b LOTIS-7 trial evaluating ZYNLONTA in combination with bispecific antibodies and other agents in B-cell non-Hodgkin lymphoma. Company releases have highlighted response rates, safety findings, and enrollment milestones from LOTIS-7, as well as anticipated timelines for sharing full data and pursuing regulatory and compendia strategies.
Investors and followers of ADCT news will also find announcements on preliminary revenue and cash estimates, participation in healthcare conferences, and equity-related actions such as employee inducement grants and private placements. These items appear in both press releases and related Form 8-K filings, giving context on the company’s commercial performance and financing plans alongside its clinical pipeline.
This news page aggregates such disclosures so readers can track ADCT’s key events, from clinical trial readouts and investigator-initiated study updates in indolent lymphomas to progress on its early-stage PSMA-targeting ADC. For those monitoring ADCT stock, revisiting this page provides a consolidated view of the company’s evolving clinical, regulatory, and corporate narrative.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
PharmaVentures has announced the opening of a new office in Seoul, South Korea, as part of its strategic expansion to support Korean biopharma companies. JungHyun Eom will be based in Seoul, enhancing the firm's engagement with the rapidly growing Korean biotech sector. With over 30 years of experience, PharmaVentures has successfully facilitated over 40 transactions linking Western pharma with Korean innovators. The firm also collaborates with Korean government institutions and financial groups to bolster the global presence of the Korean biopharma industry.
ADC Therapeutics (NYSE: ADCT) has filed its Annual Report on Form 20-F with the SEC for the fiscal year ending December 31, 2022. This report is accessible on the SEC's website and the company's investor site. ADC Therapeutics is focused on advancing targeted antibody drug conjugates (ADCs), particularly ZYNLONTA, which is FDA-approved for treating relapsed or refractory diffuse large B-cell lymphoma. The company is also developing multiple ADCs in clinical and preclinical phases. Looking ahead, forward-looking statements highlight potential risks, including achieving sales guidance and managing operational expenses.